Literature DB >> 3141672

Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP. Protocol of study I, osteoporosis trial Hannover.

R D Hesch1, J Heck, G Delling, E Keck, J Reeve, H Canzler, O Schober, H Harms, E F Rittinghaus.   

Abstract

In contrast to prevention, the therapy of manifest osteoporosis remains a clinically significant problem. So far all therapeutic attempts have yielded unsatisfying results. For this reason we have tried to achieve a positive bone balance by sequential stimulation and inhibition of the osseous metabolism. The therapy consisted of six 14-day courses with 400 units (1-38)hPTH per day and, in addition, starting with the 2nd week of PTH therapy, EHDP 5 mg per kg body weight per day for a total of 2 weeks. Already the initial therapeutic course resulted in a stimulation of decreased bone metabolism which could be documented by an increase in the calcium-47 accretion rate (six patients). An increase of the alkaline phosphatase could be noted (four patients); this, however, did not correlate with the calcium accretion. A positive calcium balance could, nonetheless, only be attained in four of eight patients within this period, while neither the alkaline phosphatase nor the kinetics would allow a prediction of this effect. Changes of the balance coincided with equal changes in the net calcium absorption. The urinary calcium excretion increased temporarily during the therapeutic phase. We were not able to detect an influence on the vitamin D metabolites. Histomorphometric studies did not demonstrate an increase in bone mass in the iliac creast after six therapeutic courses. Nevertheless, progressive deformations of vertebral bodies did not occur. We conclude that already after 2 weeks this therapeutic concept can lead to a stimulation of bone metabolism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141672     DOI: 10.1007/bf01738113

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  22 in total

1.  A new method for calculating the accretion rate of bone calcium and some observations on the suitability of strontium-85 as a tracer for bone calcium.

Authors:  J Reeve; R Wootton; B Hesp
Journal:  Calcif Tissue Res       Date:  1976-04-20

2.  Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.

Authors:  G F Mazzuoli; M Passeri; C Gennari; S Minisola; R Antonelli; C Valtorta; E Palummeri; G F Cervellin; S Gonnelli; G Francini
Journal:  Calcif Tissue Int       Date:  1986-01       Impact factor: 4.333

Review 3.  Treatment of osteoporoses by manipulation of coherent bone cell populations.

Authors:  H M Frost
Journal:  Clin Orthop Relat Res       Date:  1979-09       Impact factor: 4.176

Review 4.  The pathomechanics of osteoporoses.

Authors:  H M Frost
Journal:  Clin Orthop Relat Res       Date:  1985-11       Impact factor: 4.176

5.  Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells.

Authors:  J R Farley; J E Wergedal; D J Baylink
Journal:  Science       Date:  1983-10-21       Impact factor: 47.728

6.  The ADFR concept revisited.

Authors:  H M Frost
Journal:  Calcif Tissue Int       Date:  1984-07       Impact factor: 4.333

7.  Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone.

Authors:  M Gunness-Hey; J M Hock
Journal:  Metab Bone Dis Relat Res       Date:  1984

8.  Pathological and therapeutic implications of the cellular and humoral responses to parathyrin.

Authors:  J A Parsons; P Meunier; R Podbesek; J Reeve; R W Stevenson
Journal:  Biochem Soc Trans       Date:  1981-10       Impact factor: 5.407

9.  Increase of whole-body calcium and skeletal mass in normal and osteoporotic adult rats treated with parathyroid hormone.

Authors:  E Hefti; U Trechsel; J P Bonjour; H Fleisch; R Schenk
Journal:  Clin Sci (Lond)       Date:  1982-04       Impact factor: 6.124

10.  Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients.

Authors:  D M Slovik; J S Adams; R M Neer; M F Holick; J T Potts
Journal:  N Engl J Med       Date:  1981-08-13       Impact factor: 91.245

View more
  7 in total

Review 1.  Toward a cure for osteoporosis: reversal of excessive bone fragility.

Authors:  C H Turner
Journal:  Osteoporos Int       Date:  1991-10       Impact factor: 4.507

Review 2.  Bisphosphonates and osteoporosis.

Authors:  O H Sørensen; T Storm; G Thamsborg; H A Sørensen; G Kollerup; T Steiniche; F Melsen; H K Genant
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

Review 3.  New bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

Review 4.  The role of bisphosphonates in the prevention and treatment of osteoporosis.

Authors:  J Y Reginster
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

5.  Effects of teriparatide retreatment in osteoporotic men and women.

Authors:  Joel S Finkelstein; Jason J Wyland; Benjamin Z Leder; Sherri-Ann M Burnett-Bowie; Hang Lee; Harald Jüppner; Robert M Neer
Journal:  J Clin Endocrinol Metab       Date:  2009-04-28       Impact factor: 5.958

6.  Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients.

Authors:  R D Hesch; U Busch; M Prokop; G Delling; E F Rittinghaus
Journal:  Calcif Tissue Int       Date:  1989-03       Impact factor: 4.333

Review 7.  Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Authors:  G A Wells; A Cranney; J Peterson; M Boucher; B Shea; V Robinson; D Coyle; P Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.